Table 2 Study characteristics
Authors/year | Economic outcome measures | Time horizon | Sensitivity analysis | Influential parameters | Treatment | Discount rate (%) | Funding |
|---|---|---|---|---|---|---|---|
Fust et al., 2017 [23] | Cost per QALY, cost per FN averted and cost per LYs | Lifetime | Deterministic and Probabilistic | RR of FN, mortality RR, RDI, and medication cost | R-CHOP | 1.5 | Amgen, Biotechnology company |
Ravangard et al. 2017 [33] | Cost per FN averted | Not specified | Deterministic | Medication cost | ESHAP | NA | Not reported |
Wang et al., 2016 [24] | Cost per QALY and cost per FN averted | 18 weeks | Probabilistic Deterministic and TWSA | Medication cost, FN avoided | R- CHOP | NA | Not reported |
Lathia et a.l, 2013 [19] | Cost per QALY | 18 weeks | Deterministic and Probabilistic | Hospitalization and medication cost | R-CHOP | NA | CIHR and Amgen Canada, Biotechnology company |
Perrier et al.2013 [32] | Cost per FN averted | 100 days | Deterministic and Probabilistic | Length of hospital stay and Medication cost | Not specified | NA | Amgen, Biotechnology company |
Sebban et al.2012 [31] | Cost per FN averted | 100 days | Deterministic and Probabilistic | Medication cost | Not specified | NA | Amgen, Biotechnology company |
Whyte et al., 2011 [21] | Cost per QALY | Lifetime | Probabilistic | RR of FN, CET, RDI, age at dignosis and medication cost | R + CHOP | 3.5 | Amgen, Biotechnology company |
Lyman et al., 2009 [22] | Cost per QALY, cost per LYs, cost per FN averted | Lifetime | Deterministic and Probabilistic | Medication cost, RR of FN, mortality RR, and baseline risk | CHOP | 3 | Amgen, Biotechnology company |